parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in vascular smooth muscle cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	6 Parkinson's papers of 270	0.74
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 14632

ZFHX3 in dopamine neurons, braak-0.10 (p 0.803) → -0.14 (p 0.714)receipt 14640
ZFHX3 in microglia, braak+0.05 (p 0.906) → +0.20 (p 0.607)receipt 14639

receipt 14640: ZFHX3 in dopamine neurons, braak

power: full sample -0.12 (p 0.640, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.11 (p 0.671, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.24 (p 0.341, n 18). could be the mix.
skeptic: leave-one-out range -0.25 to -0.01, sign flips 0; without severely affected donors -0.12 (p 0.640, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZFHX3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14639: ZFHX3 in microglia, braak

power: full sample +0.05 (p 0.854, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.834, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.17 (p 0.504, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.19, sign flips 5; without severely affected donors +0.05 (p 0.854, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZFHX3 in microglia.

case closed: nothing better to follow up.

loading the receipts